Condition
Imatinib
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 4 (1)
Trial Status
Unknown2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04677439Phase 4Unknown
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
NCT01216085Phase 2Completed
An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints
NCT01316458Phase 2Completed
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
NCT01564836Not ApplicableUnknown
Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib
Showing all 4 trials